Abstract
Numerous lines of evidence implicate a role of myeloperoxidase (MPO) in the pathogenesis of cardiovascular disease (CVD). It is a well accepted fact that patients with chronic kidney disease (CKD) are at an increased risk for CVD. MPO is a pro-oxidant enzyme which could be involved in the increased susceptibility of these patients to CVD. Hence, the levels of plasma MPO was determined in healthy controls as well as in patients with CKD [stratified with the level of their kidney failure as CKD stages II–V (end stage renal disease)]. Plasma MPO was assayed by a spectrophotometric method. Serum urea and creatinine were estimated on a clinical chemistry analyzer using standard laboratory procedures. The mean plasma MPO levels were significantly lower with advancing stages of renal failure (P < 0.001). There was a positive correlation between MPO and GFR (r = +0.89, P < 0.001) and a negative correlation with urea (r = −0.85, P < 0.001) and creatinine (r = −0.82, P < 0.001). While an inverse association was observed between plasma MPO and urea in CKD patients, such an association was not observed in control subjects (P = 0.43). In conclusion, the decline in plasma MPO levels may be due to the inhibitory effect of uraemic toxins on the enzyme.
Similar content being viewed by others
References
Hampton MB, Kettle AJ, Winterbourn CC. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood. 1998;92:3007–17.
Podrez EA, Abu-soud HM, Hazen SL. Myeloperoxidase generated oxidants and atherosclerosis. Free Radic Biol Med. 2000;28:1717–25.
Brown KE, Brunt EM, Heinecke JW. Immunohistochemical detection of myeloperoxidase and its oxidation products in Kupffer cells of human liver. Am J Pathol. 2001;159:2081–8.
Winterbourn CC, Kettle AJ. Biomarkers of myeloperoxidase derived hypo chlorous acid. Free Radic Biol Med. 2000;29:403–9.
Heinecke JW. Mechanisms of oxidative damage by myeloperoxidase in atherosclerosis and other inflammatory disorders. J Lab Clin Med. 1999;133:321–5.
Vita JA, Brennan ML, Gokce N, Mann SA, Goormastic M, Shishehbor MH, et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation. 2004;110:1134–9.
Brennan ML, Penn MS, Vn Lente FV, Nambi V, Shishehbor MH, Aviles RJ. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349:1595–604.
Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–47.
Levey AS, Coresh J, Greene T et al. Expressing the MDRD study equation for estimating GFR with IDMS traceable (gold standard) serum creatinine values. J Am Soc Nephrol 2005;16:69A.
Krueger AJ, Yang JJ, Roy TA, Robbins DJ, Mackerer CR. An automated myeloperoxidase assay. Clin Chem. 1990;36:158.
Arsenault BJ, Stroes ES, Boekholdt SM. Is myeloperoxidase a useful marker to predict the risk of cardiovascular events? Curr Cardiovasc Risk Rep. 2009;3:137–43.
Weiner DE, Tighiourat H, Amin MG, Stark PC, Macleod B, Griffith JL, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15:1307–15.
Malle E, Buch T, Grone HJ. Myeloperoxidase in kidney disease. Kidney Int. 2003;64:1956–67.
Maruyama Y, Lindholm B, Stenvinkel P. Inflammation and oxidative stress in ESRD—the role of myeloperoxidase. J Nephrol. 2004;17(Suppl 8):72–6.
Capeillere BC, Gausson V, Nguyen AT, Descamps LB, Drueke T, Witko SV. Respective role of uraemic toxins and myeloperoxidase in the uraemic state. Nephrol Dial Transplant. 2006;21:1555–63.
Slungaard A, Mahoney JR. Thiocyanate is the major substrate for eosinophil peroxidase in physiologic fluids. J Biol Chem. 1991;266:4903–10.
Dirnhuber P, Schutz F. The isomeric transformation of urea into ammonium cyanate in aqueous solutions. Biochem J. 1948;42:628–32.
Mingwei Q, John WE, Simon PW. Cyanate-mediated inhibition of neutrophil myeloperoxidase activity. Biochem J. 1997;326:159–66.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Madhusudhana Rao, A., Anand, U. & Anand, C.V. Myeloperoxidase in Chronic Kidney Disease. Ind J Clin Biochem 26, 28–31 (2011). https://doi.org/10.1007/s12291-010-0075-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12291-010-0075-1